Dosage form for providing ascending dose of drug

A drug and dose technology, applied in drug delivery, drug combination, drug formulation, etc., can solve problems such as inability to overcome inherent defects

Inactive Publication Date: 2009-09-02
ALZA CORP
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Known sustained-release dosage forms cannot overcome their own inherent shortcomings

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dosage form for providing ascending dose of drug
  • Dosage form for providing ascending dose of drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] A dosage form designed and adapted for administration with an increasing release rate profile is prepared according to this example.

[0050] First, the composition of the first layer containing the drug dose was prepared as follows. 157.8 g of polyethylene oxide having a number average molecular weight of 200,000 was passed through a No. 40 mesh U.S. sieve and placed in the bowl of a conventional planetary mixer. Next, 31.2 g of methylphenidate drug was added to the blender. Then, 10 g of hydroxypropylmethylcellulose with a number average molecular weight of 9200 passed through a 40-mesh sieve and added to a mixer containing methylphenidate and polyethylene oxide. Thereafter, 0.5 g of FD&C Blue Dye No. 1 for identification was added to the drum of the blender. The ingredients were blended in a blender for 10 minutes to obtain a homogeneous composition. Next, under continuous stirring, about 100 ml of denatured absolute ethanol was gradually added to the mixer over a...

Embodiment 2

[0057] This example is prepared according to the method of Example 1, the difference is that the first layer and the second layer of drugs in this example are selected from amphetamine, dextroamphetamine, methamphetamine, ethylphenidate, amphetamine and phenetamine English, wherein the dose of the drug in the second layer is greater than the dose of the same drug in the first layer, the first layer contains 10ng to 300mg of drug and the second layer has a drug dose of 50mg to 500mg.

Embodiment 3

[0059] A dosage form was prepared according to this example which was designed and adapted for the administration of pseudoephedrine hydrochloride with a gradually increasing release rate profile.

[0060]First, the pharmaceutical composition of the first layer is prepared as follows. 139g of polyethylene oxide with a number average molecular weight of 300,000 passed through a 40-mesh sieve, and the first sieved hydrophilic polymer was put into the drum of the mixer. Next, 40 g of pseudoephedrine hydrochloride was added to the blender and the components were blended for 5 minutes. Then, 10 g of hydroxypropylmethylcellulose with a number average molecular weight of 9200 and 10 g of polyoxyethylene stearate 40 were passed through a 40-mesh sieve and added to a blender filled with the above components. Thereafter, all components were stirred together for 10 minutes to obtain a homogeneous composition. Next, under continuous stirring, about 100 ml of denatured absolute ethanol w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A bilayer and trilayer tablet and a dosage form are disclosed for administering a controlled and increasing dose of drug over time. A method is disclosed also for administering an increasing dose of drug over time.

Description

[0001] This application was submitted on August 8, 1997, the application number is 97197439.X, and the title of the invention is a divisional application of "dosage form with gradually increasing drug dosage". field of invention [0002] The present invention relates to dosage forms in which the drug is administered in increasing doses. The present invention also relates to dosage forms comprising varying concentrations of drug for the administration of therapy at slowly increasing rates. The invention also relates to a layered formulation for use in dosage form, comprising a first layer and a second layer, each layer comprising a first concentration and a second concentration of drug. The present invention also relates to a method of obtaining a therapeutic effect by administering a dosage form of a drug in which an initial dose is administered, followed by sequentially increasing doses over time. Background technique [0003] Over time, every class of society has benefite...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K45/00A61K47/30A61P25/26A61P25/20A61P25/04A61P25/00A61K9/00
CPCA61K9/0004A61P25/00A61P25/04A61P25/20A61P25/26
Inventor P·施瓦纳德A·D·阿耶J·D·威里格特A·拉穆L·G·哈默尔
Owner ALZA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap